Brilacidin shown to inhibit multiple alphaviruses, the bunyavirus Rift Valley Rift Fever, and Echovirus (a non-enveloped picornavirus)
WAKEFIELD, MA / ACCESSWIRE / September 15, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that new Brilacidin antiviral data, based on research conducted by scientists at George Mason University's Center for Infectious Disease Research (formerly NCBID), was presented at the 2022 Military Health System Research Symposium (MHSRS), held this week at the Gaylord Palms Resort and Convention Center, Kissimmee, FL. The corresponding scientific poster is available on the Company's website at the link below.
Across multiple cell lines and under different testing conditions, research showed Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Sindbis Virus (SINV). Brilacidin also was shown to inhibit Rift Valley Fever Virus (RVRF), a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load.
The in vitro evaluation of Brilacidin's antiviral activity was expanded to Echovirus, a non-enveloped picornavirus, to assess Brilacidin's effect on early viral entry in contrast to its ability to disrupt the lipid membranes of enveloped viruses. Brilacidin was shown to inhibit Echovirus, suggesting Brilacidin possesses additional antiviral mechanisms beyond its ability to directly impact viral envelopes.
Collectively, these data support Brilacidin's potential to be developed as a broad-spectrum antiviral.
Beyond research presented at the MHSRS, Brilacidin is being studied by NIH/NIAID-affiliated researchers in different viruses. Findings from this research, as well as results from the Company's Phase 2 clinical trial of intravenous Brilacidin in hospitalized cases of moderate-to-severe COVID-19 (NCT04784897) -- which showed beneficial treatment effects -- are being prepared for publication. Three years into the COVID-19 pandemic, followed by a worldwide monkeypox outbreak, it is clear effective broad-spectrum antiviral prevention and treatment strategies are needed.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, and infectious diseases. The Company is also active in evaluating other potential investment opportunities that can add value and diversify its portfolio.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future product development plans, including with respect to specific indications; statements regarding the therapeutic potential and capabilities of the StingRay System; future regulatory developments; and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals in the United States and other jurisdictions, including without limitation that compounds and devices may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere; prior test results may not be replicated in future studies and trials; the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development, including the amount and timing of the sale of shares of common stock under securities purchase agreements; and the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments. A more complete description of these and other risk factors is included in the Company's filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the Company's ability to control or predict. You should not place undue reliance on any forward-looking statements. The forward-looking statements speak only as of the information currently available to the Company on the date they are made, and the Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACTS
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
SOURCE: Innovation Pharmaceuticals Inc.
View source version on accesswire.com:
https://www.accesswire.com/716083/New-In-Vitro-Data-Supporting-the-Broad-Spectrum-Antiviral-Activity-of-Innovation-Pharmaceuticals-Brilacidin-Presented-at-2022-Military-Health-System-Research-Symposium
